The half life of Wegovy 0.25mg and what it means for how the medicine works

Why a one-week half life means the 0.25mg pen is doing more than it looks like

The decision many people face at the start of Wegovy treatment is: why am I only on 0.25mg, and when does it start working? The answer sits inside the pharmacology. Semaglutide's half life of roughly seven days means that after each weekly injection, the medicine clears your system slowly and steadily. During the first few weeks, each new injection adds to the residual amount still circulating, so blood levels climb incrementally rather than spiking and dropping like a short-acting medicine would.

At 0.25mg, the absolute amount of semaglutide is modest by design. The prescribing information is clear that this is a starting dose chosen for tolerability, not for weight-loss efficacy. Your gut, which GLP-1 receptor agonists act on directly, needs time to adjust to the medicine's effects (slower gastric emptying, altered appetite signalling) without the nausea that a higher opening dose would likely cause. So the 0.25mg stage is doing something genuinely useful: it is training your body to tolerate semaglutide before the dose steps up. You can read the full clinical overview of semaglutide on the semaglutide treatment page, which covers mechanism and licensed use in one place.

For a thorough look at how concentration changes week by week, the semaglutide half life chart maps the build-up visually, useful if you prefer to see the curve rather than read the numbers.

Steady state: the point where the half life starts to matter most

A medicine reaches steady-state concentration after roughly four to five half lives, which, for semaglutide, means four to five weeks of weekly dosing. At that point, the amount entering your system each week roughly matches the amount being cleared, and blood levels stabilise. This is when the clinical effects of any given dose are most consistently experienced, including appetite suppression, reduced food intake, and the downstream effect on body weight that the STEP 1 trial (published in the New England Journal of Medicine) measured over 68 weeks.

What this means practically is that the 0.25mg dose's tolerability purpose is usually complete by the time steady state is reached. The standard titration schedule moves to 0.5mg after four weeks, at which point a new steady state begins to establish itself over the following four weeks. Each step up follows the same logic. The long half life is, in this sense, an asset: it prevents the peaks and troughs in drug concentration that would make appetite suppression erratic, and it keeps the once-weekly schedule clinically sound rather than a convenience compromise.

If you are curious about how the full titration ladder is structured and what the peak concentration windows look like at each step, the Wegovy peak and half life page covers that in detail. The broader semaglutide half life page also addresses how the figure compares across different formulations.

What the half life tells you about missed doses and treatment continuity

The practical decision this page is really about is continuity: what does it mean for your treatment if you miss a dose, delay an injection, or are wondering whether stopping for a week matters? The one-week half life is central to all of these questions. Because semaglutide clears slowly, a single missed injection does not wipe out your steady-state levels immediately. NHS guidance on weight-management injections advises checking the Patient Information Leaflet and speaking to your prescriber if you miss a dose, because the correct response depends on how much time has passed, advice that is dose-agnostic and applies at 0.25mg just as much as at 2.4mg.

At the 0.25mg stage specifically, the lower absolute concentration means the margin is thinner: you have less circulating semaglutide to cushion a gap, and steady state at this dose is already modest. Stopping the medicine entirely is a longer conversation; the question of how long Wegovy treatment lasts involves more than half life alone, but the pharmacokinetics are part of the picture there too.

One thing our prescribers hear fairly often is the worry that a delayed pen delivery will undo weeks of progress. The pharmacology provides some reassurance (the long half life means a short delay is less disruptive than it would be for a daily medicine) but the right answer for your specific timing should always come from your prescriber, not from a general rule. The cost and logistics of keeping supply consistent matter too, and how treatment supply works through a regulated UK pharmacy is worth understanding before you start. If you have broader questions, the nume FAQs cover the most common ones.

If you are at the stage of thinking about whether Wegovy is the right treatment for you at all, the Wegovy overview and weight-loss treatment options pages sit alongside each other and are worth reading together. For the 0.25mg pen itself (its presentation and what to expect) the 0.25mg Wegovy page is the specific reference. And if you want to understand how our prescribers approach all of this, our clinical team page sets out the oversight behind every consultation.

Wegovy is a prescription-only medicine. A prescriber assesses suitability, reviews your health history, and determines the right pace of titration for you, the half life is one input among many. If you are ready to explore whether treatment is appropriate, speaking to our prescribers is the next step. Start your free consultation and a GPhC-registered prescriber will review your case the same day.